Full-Time
Solutions Engineer
Product Expert, Housing
Updated on 8/1/2026
EliseAI
501-1,000 employees
AI-driven real estate and healthcare automation
Compensation Overview
CA$135k - CA$180k/yr
Toronto, ON, Canada
In Person
Four to five days in the Toronto office per week are required; travel up to 20% is expected.
 Sales & Solution Engineering (1) |
|---|
Get referred to EliseAI
See people who can refer or advise you
- At least 3 years of experience in a Solutions Engineer role at a software-as-a-service company.
- Willingness to travel up to 20% to meet and engage with prospective clients.
- Strong understanding of product development and launch processes.
- Strong problem-solving skills and the ability to troubleshoot technical issues.
- Experience working with cross-functional teams, including engineering, operations, and product management.
- Strong communication skills, with the ability to explain complex technical concepts to non-technical stakeholders.
- Familiarity with customer relationship management tools and support ticketing systems.
- Ability to manage multiple tasks and priorities in a fast-paced environment.
- Ability to work independently and as part of a team, with a proactive approach to problem-solving and support.
- Willingness to work in person at the office 4–5 days per week.
- Conduct thorough discovery sessions with new clients to understand their product area and requirements.
- Act as the representative for Support Engineers within the product area, ensuring alignment and collaboration.
- Develop and maintain roadmaps for self-serve launch tools and internal launch settings, including quality assurance processes.
- Provide in-depth technical support and guidance to prospects, including product demonstrations, presentations, and explanations of complex technical concepts.
- Guide Customer Success Managers through product implementations and act as a partner for training and escalation issues.
- Provide troubleshooting support for clients after launch, addressing and resolving issues within the product area.
- Develop an in-depth understanding of how the product works to meet client needs effectively, ensuring comprehensive knowledge transfer and support.
- Attract top-tier talent to join the team.
- Experience with quality assurance processes and developing self-serve tools.
EliseAI offers a SaaS platform that automates conversations and scheduling for businesses, with modules that connect to PMS, CRM, and calendar tools to keep data in sync. In real estate, it handles inquiries, lead qualification, tour scheduling (including self-scheduling) and virtual tours, while in healthcare it manages patient inquiries and appointment bookings. The system integrates with third-party apps and tracks outcomes such as 50% of tour appointments driven by its AI and 27% after-hours bookings. Its goal is to reduce manual work and speed up customer interactions to improve operational efficiency and satisfaction.
Company Size
501-1,000
Company Stage
Series E
Total Funding
$391.9M
Headquarters
New York City, New York
Founded
2017
Get referred to EliseAI
See people who can refer or advise you
Simplify's Take
What believers are saying
- One in six U.S. apartments now uses EliseAI software.
- New Manhattan headquarters supports hiring and product expansion.
- Healthcare automation expands beyond leasing into patient intake and scheduling.
What critics are saying
- General-purpose AI agents can copy scheduling and follow-up workflows quickly.
- Yardi, RealPage, and Entrata can bundle competing native AI features.
- Healthcare deployments face HIPAA compliance failures and security review delays.
What makes EliseAI unique
- Deeply integrated AI workflow automation for housing and healthcare.
- Embedded Zillow Rentals AI Assist lifted lead-to-application conversion 43%.
- Passed $200 million ARR after five straight years of 100% growth.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Equity in the company in the form of stock options
Medical, Dental and Vision premiums covered at 100%
Fully paid parental leave
Commuter benefits
401k benefits
Monthly fitness stipend
Fun company social events through our Elise and the City program
Unlimited vacation and paid holidays
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 2%2 year growth
↑ 4%EliseAI opens new headquarters office in Manhattan. The company has opened the New York City office location it announced back in January. Published on Jul. 20, 2026 Photo: EliseAI via LinkedIn Rose Velazquez EliseAI, a company that provides the housing and healthcare industries with agentic workflow solutions, has opened its new headquarters office in Manhattan. The company previously announced it signed a 10-year lease for this space in January. The facility is located in a Midtown office building at 401 Fifth Ave. The site, which was formerly the Tiffany & Co. building, spans eight floors and offers 240,000 square feet of space. EliseAI, a company with over 400 employees, occupies 109,000 square feet in the building, an increase of more than 1.5x over its previous New York office. EliseAI's new facility is designed to foster collaboration and provide room for future company growth. "New York is very special to us; it's where we started building EliseAI," Minna Song, the company's co-founder and CEO, said in a January statement. "Choosing our new home here was critical due to our strong in-person culture and our commitment to creating a truly exceptional experience for our people to collaborate and do their best work. The new space will let us further scale our New York team, contribute to the city's technology ecosystem, and build the next chapter of AI in housing and healthcare."
Company news. Showing 21 of 66 posts Materna Medical announces successful $5 million B3 financing to support transformational year ahead. Materna Medical announced the successful close of its $5 million B3 financing round, positioning the company for a year of clinical, commercial, and operational advancement. The round was led by InnovaHealth Partners, Wavemaker360 Health, and Band of Angels, with support from existing investors. July 1, 2026 EliseAI hits $200M ARR after five consecutive years of 100% growth across housing and healthcare. EliseAI, the AI company automating complex housing and healthcare systems, announced it passed $200 million in annual recurring revenue (ARR), achieving 100% year-over-year growth for the fifth consecutive year. June 10, 2026 OCULOGICA announces FDA clearance for SNAP concussion test. Oculogica, a pioneer in the development of non-invasive tests for concussion, announced the FDA has granted a 510(k) clearance for SNAP. SNAP is a 90-second concussion test that combines eye tracking with symptom severity to provide a multi-modal concussion assessment for clinicians. June 4, 2026 Zenflow presents the BREEZE(TM) pivotal clinical trial at the American urological Association annual meeting. Zenflow, Inc. presented data from its BREEZE pivotal clinical trial demonstrating the efficacy and safety of the Zenflow Spring Implant & Delivery System, which was FDA approved in Dec. 2025 for the treatment of symptoms associated with benign prostatic hyperplasia, also known as enlarged prostate. May 18, 2026 How Sylvatex is harnessing the power of nature to win the battery race america can't afford to lose. Virginia Klausmeier founded Sylvatex - a California-based company with a single, audacious goal: to make the cathode better, cleaner, and cheaper than China, on American soil, using nature's own chemistry as the blueprint. May 15, 2026 Osteoboost featured in Vogue. Osteoboost, the first FDA-cleared drug-free prescription treatment for osteopenia in postmenopausal women, was featured in the May edition of Vogue. May is Osteoporosis Awareness Month and Women's Health Month. May 11, 2026 Tot Squad acquires AI doula startup Robyn. Tot Squad, a platform that supports new parents from registry through early parenthood, has acquired Robyn, a maternal health startup with an AI-powered doula trained on over 70,000 de-identified messages between real doulas and parents. May 7, 2026 Building plant-based cities with Another Tomorrow. Sustainable ready-to-wear brand Another Tomorrow hosted its third "New Earth Dialogues" installment with architect Lindsey Wikstrom - founding principal of Mattaforma and recent recipient of the Cooper Hewitt National Design Award - to discuss. May 4, 2026 Chromatic 3D Materials demonstrates Breakthrough in 3D printed rocket propellant. Chromatic 3D Materials announced successful prototype printing and static fire testing of its additively manufactured rocket propellant. The tests demonstrated that Chromatic's printed propellant can sustain combustion pressures beyond 1800 psi without structural failure, a critical milestone. April 29, 2026 Bairitone Health receives FDA Breakthrough Device Designation for its noninvasive technology designed for obstructive sleep apnea. Bairitone Health has received Breakthrough Device Designation from the US Food and Drug Administration (FDA) for its sleep sonar for anatomic polysomnography technology to pinpoint the root cause of airway obstruction in people with obstructive sleep apnea (OSA). April 28, 2026 Kind Designs and BMI OrganBank named 2026 Villalobos Award winners by the Angel Capital Association. Two Golden Seeds companies, Kind Designs and BMI OrganBank, named as winners of the 2026 Villalobos Award by the Angel Capital Association (ACA). This award recognizes the most innovative ideas financed by members of the ACA across two categories: Technology/Services/Consumer and Life Sciences. April 22, 2026 EliseAI named on the Forbes 2026 AI 50 list. Forbes' annual AI 50 list spotlights the most promising privately-held AI companies in the world. Under the leadership of CEO Minna Song, EliseAI continues to scale its AI platform, transforming operations across housing and healthcare, driving efficiency, automation, and better experiences. April 16, 2026 Osteoboost raises $8M to scale fda-cleared wearable for bone health in postmenopausal women. Osteoboost Health has closed an $8 million financing round to scale manufacturing, expand clinical research, and broaden commercial reach for its FDA-cleared prescription wearable for low bone density. The round was led by Ambit Health Ventures. April 15, 2026 Saladax Biomedical to expand international access to drug level testing for psychiatry and oncology. Saladax Biomedical, Inc., a leader in therapeutic drug monitoring (TDM) diagnostics for psychiatry and oncology, announced a distribution agreement with Thermo Fisher Scientific to expand global access to high-quality TDM assays that help clinicians optimize patient outcomes. April 7, 2026 Joylux launches reliefher(tm), the next generation of intimate skincare for midlife women. Joylux today announced the launch of reliefHER, a proprietary vaginal hydration melt formulated with 15 mg of hyaluronic acid (HA), up to three times the HA power found in many other products. April 6, 2026 Alcatraz raises $50 million to replace the badge with your face - without sacrificing privacy. Alcatraz, which makes an AI-powered physical access control system that authenticates employees without collecting personal data, has closed a $50 million Series B funding round, bringing total capital raised to more than $100 million. April 2, 2026 MedOne and Nanodropper announce early success of MediSplit program, demonstrating reduced cost, improved adherence, and reduced side effects. MedOne and Nanodropper, a leader in precision medication delivery solutions, recently announced early results from the MediSplit program, a value-based clinical care path designed to improve medication adherence and reduce side effects for patients using prescription eye drops. April 2, 2026 Madorra enrolls first patient in pivotal trial for non-hormonal vulvovaginal atrophy treatment. Madorra, a medical device company, has enrolled the first patient in its pivotal clinical trial evaluating the Madorra Therapy System for moderate to severe vulvovaginal atrophy - a milestone following the FDA's grant of Breakthrough Device Designation. March 30, 2026 Chippin receives $1 million grant to incorporate invasive catfish in pet nutrition. Chippin, Inc., a company that leverages planet-friendly ingredients and invasive species to create sustainable pet nutrition, has received a $1 million grant through the Meat and Poultry Processing Expansion Program to create a new market for invasive catfish in pet nutrition. March 30, 2026 Breakthrough Device Designation awarded to Hemex Health for Gazelle Hb Variant Test. Hemex Health, a medical diagnostics company focused on decentralized testing for blood-based conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its Gazelle(R) Hb Variant Test. March 26, 2026 New clinical study shows Nanodropper microvolume delivery device provides superior efficacy, fewer side effects, and dramatically reduces early eyedrop bottle exhaustion. Nanodropper announced results from a randomized clinical trial demonstrating that microvolume eyedrop delivery using their adaptor achieved greater intraocular pressure reduction, fewer adverse effects, and significantly reduced premature bottle exhaustion compared with conventional eyedrops. March 25, 2026
EliseAI, an AI company automating housing and healthcare systems, has surpassed $200 million in annual recurring revenue, marking its fifth consecutive year of 100% year-over-year growth. The company now powers one in six apartments in the United States. EliseAI automates the entire resident journey in housing, from leasing enquiries to maintenance requests and renewals. In healthcare, it handles appointment scheduling, patient intake and reduces wait times, cutting administrative overhead by up to 25%. The platform addresses an industry problem costing over $600 billion annually in the US. The company has seen particular adoption among affordable housing providers operating under tight financial constraints. Co-founder and CEO Minna Song attributes the growth to solving real problems in essential industries where AI can have tangible impact.
EliseAI hits $200M ARR after five consecutive years of 100% growth across housing and healthcare. June 10, 2026 NEW YORK, June 10, 2026 - EliseAI, the AI company automating complex housing and healthcare systems, today announced it passed $200 million in annual recurring revenue (ARR), achieving 100% year-over-year growth for the fifth consecutive year. Housing and healthcare together account for more than 40% of the average American household budget. Both industries have been underserved by technology relative to their size and complexity. Automating them at scale requires state-by-state compliance, deep workflow integration, and edge-case handling that general-purpose tools cannot deliver. EliseAI has been building inside that complexity in close partnership with operators, becoming core to how they run their properties and practices. "The industries where AI matters the most are not the ones getting the most attention," said Minna Song, co-founder and CEO of EliseAI. "We started in housing, and then expanded to healthcare, because we believed AI could fundamentally change how essential industries operate. Five years of 100% growth at this stage is rare, and it happens when the problems are real and the product becomes more valuable the deeper it is embedded." EliseAI powers one in six apartments in the United States, automating the entire resident journey - from answering leasing inquiries and handling maintenance requests to following up on renewals. In healthcare, it supports patients by scheduling appointments, guiding them through intake forms, and reducing time spent waiting. The need is most acute where the margin for error is lowest. Affordable housing providers, operating under the tightest financial constraints and serving residents with the fewest alternatives, are increasingly turning to EliseAI because operational consistency is not optional when staffing is lean and residents depend on every part of the system working. It is one of the places where AI can have the most tangible impact on people's lives. "Affordable housing operators have always had to do more with less," said Joshua Greenblatt, Managing Principal at Vesta Corporation. "The compliance requirements are strict, the teams are lean, and the residents we serve often have no safety net if something falls through the cracks. EliseAI takes on the routine work that used to bottleneck our staff, so our teams can spend their time on the people, not the paperwork. For an industry that technology largely bypassed for decades, that shift is real - and it matters." Healthcare administrative costs total in excess of $600 billion annually in the U.S., $150 billion of that attributable to missed appointments alone, driven by excessive manual tasks, fragmented systems, and chronic underinvestment in technology. EliseAI is tackling the problem at the point of highest friction: front-desk and call center operations. Its platform handles complex workflows including multi-step scheduling, prior authorizations, patient intake, and nuanced clinical inquiries, accurately, compliantly, and empathetically, cutting overhead by up to 25%, slashing wait times, and reducing abandoned calls. As a result, EliseAI is increasingly where the patient experience begins. For practices facing staffing shortages and rising call volumes, the company is moving beyond task automation to become a core layer of healthcare operations. "EliseAI's growth shows what it takes to build vertical AI at scale: deep domain expertise, workflow-level product insight, and clear customer ROI," said Alex Immerman, partner, a16z Growth. "Today's news reflects EliseAI's real impact on their customers' bottom lines and sets the stage for continued growth." About EliseAI EliseAI transforms complex housing and healthcare systems. By deeply integrating into workflows and automating operations, it makes them efficient and cuts costs for all. Its platform helps property managers handle leasing, maintenance and resident engagement. EliseAI replaces fragmented tools with one integrated system that reduces manual work and improves accessibility and experience for residents and patients alike. The company is based in New York with offices in San Francisco, Boston, Chicago and Toronto and is actively hiring across all locations. To learn more, visit www.eliseai.com/careers.
ModMed AI scheduling in action: how Kansas City Skin & Cancer Center went live in 24 hours with Elise. John Durovsik April 29, 2026 The role of the dermatologist has shifted. Where patients once came in for a single mole check and didn't return for years, they now build long-term relationships with their providers, returning regularly for ongoing care. For practices, that shift makes accessibility a baseline expectation rather than a differentiator. "Dermatology is now more closely related to a primary care physician, somebody that you see on a regular basis. That accessibility we have to provide for our patients is part of where Elise comes in." Kansas City Skin & Cancer Center was thinking about exactly that question when they started evaluating EliseAI. As the practice expanded, leadership wanted to make sure every patient who called could actually reach them, without hold queues, voicemail backlogs, or the small frictions that quietly turn into lost appointments. "If you have any kind of roadblocks in getting in and making an appointment, you are going to lose patients. It is even worse to have to leave a voice message and wait for somebody to call you back. It does not provide good care for our patients. It does not feel like they have access to us." With Elise handling first contact, the practice's calls get answered, backend paperwork gets completed, and patients get scheduled without the delays that come from hold queues and callbacks. The team can spend their time on the work that actually requires them. Implementation moved quickly for a team already mid-transition. The practice had recently rolled out a new practice management system, a new phone system, and significant IT changes. "Within 24 hours of receiving an email that Elise was integrated directly with ModMed, we were up and running." Of all those transitions, the EliseAI implementation was "the most painless." The support experience reinforced the decision. The EliseAI team was responsive, hands-on, and shaped their approach around how Kansas City Skin & Cancer Center actually operates day to day. "The support that's been given to us has been worth a million bucks in a sense, because it's catered to us." Within the first week of going live, appointments were being scheduled, phone volume was dropping, and the front desk was no longer running behind. Today, Elise schedules more than 1,850 appointments per month for the practice. With every call answered, patients have a consistent way to reach Kansas City Skin & Cancer Center, and the team has room to focus on the parts of patient care that require a human. "I think it is important for every call to be taken by AI. This is basically organizing it so we can focus on what we do best." The shift in dermatology toward longitudinal care isn't slowing down. Practices like Kansas City Skin & Cancer Center are deciding what accessibility looks like in that new model, and what it takes to deliver it.